MSI-H and dMMR Testing Market Report 2025–2034 – Precision Oncology M&A and Competitive Trends

 Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the anticipated market size of the msi-h and dmmr industry over the next few years?
The MSI-H and dMMR market size has grown exponentially in recent years. It will grow from $6.15 billion in 2024 to $7.59 billion in 2025 at a compound annual growth rate (CAGR) of 23.3%. The growth in the historic period can be attributed to rising incidence of colorectal and endometrial cancers, expanded genetic screening programs, growing clinical adoption of MSI testing, increasing awareness of hereditary cancer syndromes, and a rise in liquid biopsy adoption.

The MSI-H and dMMR market size is expected to see exponential growth in the next few years. It will grow to $17.40 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, expanding applications of next-generation sequencing, rising healthcare expenditure in oncology, growing clinical trials for immune checkpoint inhibitors, and regulatory support for companion diagnostics. Major trends in the forecast period include the integration of artificial intelligence in diagnostic workflows, partnerships between pharma and diagnostic companies, the development of multiplex biomarker panels, advances in immunotherapy, and a shift toward pan-cancer biomarker testing.

Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What emerging drivers are expected to shape the future of the msi-h and dmmr market?
The rising prevalence of cancer is expected to propel the growth of the MSI-H and dMMR market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is primarily due to aging populations, as the risk of developing cancer increases significantly with age because of the cumulative effect of genetic mutations and prolonged exposure to risk factors over time. MSI-H and dMMR are used in cancer to identify tumors with high mutation rates due to defects in DNA repair mechanisms. These biomarkers help guide immunotherapy decisions, as such tumors are more likely to respond to immune checkpoint inhibitors, and they also provide insight into prognosis and potential genetic syndromes. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, in 2023, an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths were expected in the United States. These numbers are projected to rise in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, highlighting a continuing increase in cancer incidence and mortality. Therefore, the rising prevalence of cancer is driving the growth of the MSI-H and dMMR market.

What emerging segments are shaping the future landscape of the msi-h and dmmr industry?
The MSI-H and dMMR market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy
2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications
3) By Stage: Early Stages, Advanced Stages
4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which major trends are influencing the growth of the msi-h and dmmr industry?
Major companies operating in the MSI-H and dMMR market are focusing on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves using two or more treatment modalities, commonly immunotherapy agents such as checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to enhance treatment response, overcome resistance, and improve survival outcomes in patients with tumors that exhibit high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing treatment options for this challenging cancer subtype. This approval marks a significant milestone in the treatment of MSI-H and dMMR cancers, as it provides a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, addressing the unmet medical needs in this patient population.

How are key players in the msi-h and dmmr market strengthening their market position?
Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Which geographic areas are contributing significantly to the growth of the msi-h and dmmr sector?
North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can Companies Use The MSI-H And dMMR Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.

Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Need Customized Data On MSI-H And dMMR Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.

Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company